science
France Begins Reimbursing Wegovy and Mounjaro Under Strict Conditions
The French healthcare system has started reimbursing Wegovy and Mounjaro for eligible patients. France reports obesity rates lower than many EU countries yet still faces regional variation in prevalence.
en.rfi.frAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The French healthcare system began reimbursing the anti-obesity drugs Wegovy and Mounjaro for patients who meet specific medical criteria.
Patients must have a body mass index above 30 or above 27 with weight-related health conditions. Treatment requires ongoing medical supervision and documented failure of lifestyle interventions.
France records obesity rates below the EU average. Higher prevalence appears in northern and overseas departments compared with other parts of the country. The common perception that French people do not gain weight holds only partial accuracy when France is compared with peer EU nations.
Transparency
1 source · single source
CorroborationModerate · 1 source
